GLP-1 Microdosing: What the Actual Dose-Response Data Shows

"Microdosing" a GLP-1 — staying at or below the labeled starting dose indefinitely, rather than titrating up — is a real, widely discussed practice with no dedicated clinical trial behind it. A live search of the published literature for it turns up nothing purpose-built to answer the question. What does exist is something more useful: the actual dose-response data from the pivotal trials, which shows precisely what happens at each dose along the way — including the low ones.

What the pivotal trials actually tested, dose by dose

SURMOUNT-1, tirzepatide's pivotal obesity trial, randomized participants to three separate weekly maintenance doses rather than just one — a genuine dose-response design. At 72 weeks, mean weight loss was -15.0% with the 5 mg dose (the lowest labeled maintenance dose), -19.5% with 10 mg, and -20.9% with 15 mg, against -3.1% with placebo¹. That is real evidence for the microdosing question, directly on the currently approved product: the lowest approved maintenance dose still produced substantial weight loss — nearly five times placebo — but meaningfully less than the top labeled dose. Lower is not "the same, cheaper." It's measurably less, in a clean, dose-dependent line.

Semaglutide's own dose-ranging trial shows the identical pattern

Before Wegovy's weekly 2.4 mg formulation existed, an earlier phase 2 dose-ranging trial tested five separate daily semaglutide doses from 0.05 mg up to 0.4 mg against placebo and liraglutide over 52 weeks. Mean weight loss ran from -6.0% at the lowest dose (0.05 mg) up to -13.8% at the highest (0.4 mg), against -2.3% for placebo — every single dose tested beat placebo, and the relationship between higher doses and more weight loss was consistent and statistically significant at each step². Note the caveat: this trial used an older, once-daily formulation at doses not directly comparable in milligrams to today's once-weekly Wegovy schedule, so treat it as evidence of the dose-response principle rather than a literal preview of what a "microdose" of Wegovy specifically would do. The principle it demonstrates, though, is the same one SURMOUNT-1 shows on the currently marketed drug: even a low dose beats no treatment, but a clear, real gap opens up between low and target doses.

Why the labeled starting dose isn't meant to be a destination

The starting doses on both drugs' labels — 0.25 mg for Wegovy, 2.5 mg for Zepbound — are explicitly initiation doses in the FDA-labeled titration schedule, not doses tested as a long-term maintenance strategy in the pivotal trials. Zepbound's own label states its 2.5 mg starting dose "is for treatment initiation and is not approved as a maintenance dosage." Staying there indefinitely — the literal practice of "microdosing" — is a use case the trials above did not test, which is exactly why no dedicated evidence exists to say how it performs against the maintenance doses that were studied.

What this means if cost is the reason you're considering it

If the appeal of microdosing is stretching a prescription to save money, the dose-response data above answers the efficacy side honestly: less drug is likely to mean less weight loss, not the same result for less money. The better cost lever is provider selection, not self-directed underdosing — compare verified, flat-priced options on the cheapest GLP-1 board and price your real annual cost with the calculators before deciding a lower dose is the only way to make the budget work. If side effects, not cost, are the reason you're drawn to staying at a lower dose, that is a legitimate conversation to have with your prescriber directly — see what the trials report on side effects and ask about a slower-than-labeled titration rather than an indefinite stay at the starting dose. The dose-response trials behind this are indexed in our research library. Not medical advice — see our medical disclaimer; any change to your dose or schedule should go through your own clinician.